Search
Summit Therapeutics Negotiates $15 Billion Licensing Agreement with AstraZeneca for Cancer Drug
1 day ago /
Read about 0 minute
Author：小编
Summit Therapeutics is in advanced discussions with AstraZeneca regarding a potential licensing deal worth $15 billion for ivonescimab, an experimental lung cancer drug. This news has bolstered Summit Therapeutics' share price. It is noted that Summit acquired the license for ivonescimab from Kanfang Biotech in 2022, and the drug has already secured approval in China. Summit aims to file a marketing application for ivonescimab in the United States. Research indicates that, when combined with chemotherapy, ivonescimab provides superior survival rates in certain patients compared to Merck's Keytruda. Furthermore, a study in China is currently comparing ivonescimab with BeiGene's Tevimbra.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
